Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies

References

• Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Based on systematic review, increasing incidence and prevalence of the inflammatory bowel diseases with time. Gastroenterology. 2012;142:46–54.
   PubMed Web of Science ®Google Scholar
• Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut. 2019;68:1953–1960.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–297.
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta–analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–1362.
   PubMed Web of Science ®Google Scholar
• Mandel MD, Balint A, Golovics PA, et al. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: results from two referral centers. Dig Liver Dis. 2014;46:985–990.
   PubMedGoogle Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128:862–869.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021;70:1396–1405.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S. Loss of response to anti-tumor necrosis factors: what is the next step? Dig Dis. 2014;32:384–388.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to Anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
   PubMed Web of Science ®Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685–698.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Lorenzetti R, et al. Long-term real-life efficacy and safety of infliximab and Adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol. 2021;33:670–679.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.e10.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet, et al. Systematic review with meta–analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048–1064.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Ardizzone S, Biancone L, et al. Ustekinumab in the management of Crohn’s disease: expert opinion. Dig Liver Dis. 2018;50:653–660.
   PubMedGoogle Scholar
• D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015–2030.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicenter, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031–2046.
   PubMed Web of Science ®Google Scholar
• Loftus LV, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s. Disease N Engl J Med. 2023;388:1966–1980.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;16:2496–2508.
   Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14:4–22.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Papi C, Orlando A, et al. Use of biologics for the management of Crohn’s disease: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis. 2023;55:442–453.
   PubMedGoogle Scholar
• Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd edn ed. Philadelphia PA: Lippincott, Williams & Wilkins; 2008.
   Google Scholar
• Ha C, Ullman T, Siegel CA, et al. Patients enrolled in randomised controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002–1007.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490–501.
   PubMedGoogle Scholar
• Macaluso FS, Maida M, Grova M, et al. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomised controlled trials to real-world experience. Therap Adv Gastroenterol. 2021;14:17562848211010668.
   Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106.
   PubMed Web of Science ®Google Scholar
• Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (Ca2). Gastroenterology. 1995;109:129–135.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the accent I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the classic II trial. Gut. 2007;56:1232–1239.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the extend trial. Gastroenterology. 2012;142:1102–1111.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: a randomised trial. Ann Intern Med. 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:1002–1014.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48:394–409.
   PubMed Web of Science ®Google Scholar
• Barberio B, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut. 2023;72:264–274.
   PubMed Web of Science ®Google Scholar
• Targownik LTA, Singh H, Nugent Z, et al. Comparing long-term outcomes between infliximab and Adalimumab first-time users for persons with inflammatory bowel disease. Gastroenterology. 2015;148:S176.
   Web of Science ®Google Scholar
• Narula N, Kainz S, Petritsch W, et al. The efficacy and safety of either infliximab or Adalimumab in 362 patients with anti-TNF- α naive Crohn’s disease. Aliment Pharmacol Ther. 2016;44:170–180.
   PubMed Web of Science ®Google Scholar
• Kestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor- α agents. Clin Gastroenterol Hepatol. 2013;11:826–831.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Sokol H, Bourrier A, et al. Adalimumab or infliximab as monotherapy or in combination with an immunomodulator in the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2016;44:1102–1113.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Privitera AC, et al. A propensity score-matched comparison of infliximab and adalimumab in tumour necrosis factor- α inhibitor-naive and non-naive patients with Crohn’s disease: real-life data from the sicilian network for inflammatory bowel disease. J Crohns Colitis. 2019;13:209–217.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and Adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:811–817.e3.
   PubMed Web of Science ®Google Scholar
• Singh S, Andersen NN, Andersson M, et al. Comparison of infliximab with Adalimumab in 827 biologic-naïve patients with Crohn’s disease: a population-based Danish cohort study. Aliment Pharmacol Ther. 2018;47:596–604.
   PubMed Web of Science ®Google Scholar
• Peters CP, Eshuis EJ, Toxopeus FM, et al.; North Holland GUT club. Adalimumab for Crohn’s disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis. 2014;8:866–875.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Salleron J, Filippi J, et al. Anti-TNF monotherapy for Crohn’s disease: a 13-year multicenter experience. J Crohns Colitis. 2016;10:516–524.
   PubMed Web of Science ®Google Scholar
• Seo H, Ye BD, Song EM, et al. Long-term outcomes of Adalimumab treatment in 254 patients with Crohn’s disease: a hospital-based cohort study from Korea. Dig Dis Sci. 2017;62:2882–2893.
   PubMed Web of Science ®Google Scholar
• Orlando A, Renna S, Mocciaro F, et al. Six year Adalimumab efficacy in steroid-dependent Crohn’s disease patients: a prospective single-center real life study. Dig Liver Dis. 2016;48:1314–1317.
   PubMedGoogle Scholar
• Tursi A, Elisei W, Picchio M, et al. Effectiveness and safety of infliximab and Adalimumab for ambulatory Crohn’s disease patients in primary gastroenterology centers. Eur J Intern Med. 2014;25:485–490.
   PubMed Web of Science ®Google Scholar
• Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013;19:1622–1630.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Lorenzetti R, et al. Long-term real-life efficacy and safety of infliximab and Adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol. 2021;33:670–679.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Dreesen E, Papamichael K, et al. How, when, and for whom should we perform therapeutic drug monitoring? Clin Gastroenterol Hepatol. 2020;18:1291–1299.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Mao R, Chen M. Optimising biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7:171–185.
   PubMed Web of Science ®Google Scholar
• Casteele NV, Herfarth H, Katz J, et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835.e6–857.e6.
   Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–1668.
   PubMed Web of Science ®Google Scholar
• Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;116:2014–2025.
   PubMed Web of Science ®Google Scholar
• Nguyen NH, Solitano V, Vuyyuru SK, et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis. Gastroenterology. 2022;163:937–949.e2.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV, Faubion A, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–1139.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Ben-Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol. 2014;27:304–312.
   PubMedGoogle Scholar
• Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613–623.
   PubMed Web of Science ®Google Scholar
• Casanova MJ, Chaparro M, Minguez M, et al. Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the eneida registry. Inflamm Bowel Dis. 2020;26:606–616.
   PubMed Web of Science ®Google Scholar
• Doherty G, Katsanos KH, Burisch J, et al. European Crohn’s and colitis organisation topical review on treatment withdrawal [‘Exit Strategies’] in inflammatory bowel disease. J Crohns Colitis. 2018;12:17–31.
   PubMed Web of Science ®Google Scholar
• Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174–179.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43:910–923.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marin AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;111:632–647.
   PubMed Web of Science ®Google Scholar
• Louis E, Resche-Rigon M, Laharie D, et al. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicenter, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8:215–227.
   PubMed Web of Science ®Google Scholar
• Van der Valk ME, Mangen M-J-J, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalization and surgery towards anti-TNFa therapy: results from the COIN study. Gut. 2014;63:72–79.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685–1696.
   PubMed Web of Science ®Google Scholar
• Scott FI, Lichtenstein GR. Biosimilars in the treatment of inflammatory bowel disease: supporting evidence in 2017. Curr Treat Options Gastroenterol. 2018;16:147–167.
   PubMedGoogle Scholar
• Smits LJT, Derikx LAAP, de Jong DJ, et al. Clinical outcomes following a switch from Remicade® to the Biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–1293.
   PubMed Web of Science ®Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11:690–696.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23:233–243.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Fiorino G, Variola A, et al. The PROSIT Cohort of infliximab biosimilar in IBD: a prolonged follow-up on the effectiveness and safety across Italy. Inflamm Bowel Dis. 2019;25:568–579.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Viola A, et al. The SPOSIB SB2 Sicilian Cohort: safety and effectiveness of infliximab biosimilar SB2 in inflammatory bowel diseases, including multiple switches. Inflamm Bowel Dis. 2021;27:182–189.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Cappello M, Busacca A, et al. SPOSAB ABP 501: a sicilian prospective observational study of patients with inflammatory bowel disease treated with adalimumab biosimilar ABP 501. J Gastroenterol Hepatol. 2021;36:3041–3049.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohn’s Colitis. 2017;11:26–34.
   Google Scholar
• Tursi A, Mocci G, Allegretta L, et al. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opin Biol Ther. 2022;22:313–320.
   PubMed Web of Science ®Google Scholar
• Cingolani L, Barberio B, Zingone F, et al. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as Adalimumab originator. Sci Rep. 2021;11:10368.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Allegretta L, et al. Comparison of performances of adalimumab biosimilars SB5, APB501, GP2017, and MSB11022 in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study. Inflamm Bowel Dis. 2022;29:376–383.
   Web of Science ®Google Scholar
• Tapete G, Bertani L, Pieraccini A, et al. Effectiveness and safety of non-medical switch from adalimumab originator to SB5 biosimilar in patients with inflammatory bowel diseases: twelve-month follow-up from the TABLET registry. Inflamm Bowel Dis. 2022;28:62–69.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Cuomo A, et al. Replacement of adalimumab originator to adalimumab biosimilar for a non-medical reason in patients with inflammatory bowel disease: a real-life comparison of adalimumab biosimilars currently available in Italy. J Gastrointestin Liver Dis. 2022;31:411–416.
   PubMed Web of Science ®Google Scholar
• Lukas M, Malickova K, Kolar M, et al. Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical center. J Crohns Colitis. 2020;14:915–919.
   PubMed Web of Science ®Google Scholar
• Trystram N, Abitbol V, Tannoury J, et al. Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021;53:887–899.
   PubMed Web of Science ®Google Scholar
• Hanzel J, Jansen JM, Ter Steege RWF, et al. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study. Inflamm Bowel Dis. 2022;28:495–501.
   PubMed Web of Science ®Google Scholar
• Derikx LAAP, Dolby HW, Plevris N, et al. Effectiveness and safety of Adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve SB5 observational cohorts. J Crohns Colitis. 2021;15:2011–2021.
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Tribocco E, Rosso C, et al. Switching from biosimilar to biosimilar Adalimumab, including multiple switching, in Crohn’s disease: a prospective study. J Clin Med. 2021;10:3387.
   PubMed Web of Science ®Google Scholar
• Strik AS, D’Haens GR, Löwenberg M. Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: a case report. Clin Case Rep. 2019;7:2049–2053.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomised controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160:2340–2353.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Fumery M, Leong RW, et al. Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. Expert Rev Clin Immunol. 2023;19:1143–1156.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicenter cohort study. J Crohns Colitis. 2022;16:1436–1446.
   PubMed Web of Science ®Google Scholar
• Huguet JM, García-Lorenzo V, Martí L, et al. Subcutaneous infliximab [CT-P13], a true biologic 2.0. Real clinical practice multicenter study. Biomedicines. 2022;10:2130.
   PubMed Web of Science ®Google Scholar
• Bermejo F, Guerra I, Algaba A, et al. Pharmacological approach to the management of Crohn’s disease patients with perianal disease. Drugs. 2018;78:1–18.
   PubMed Web of Science ®Google Scholar
• Panes J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652–664.
   PubMed Web of Science ®Google Scholar
• Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn’s disease: future directions. Gut. 2018;67:1181–1194.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58:940–948.
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–3497.
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722–729.
   PubMed Web of Science ®Google Scholar
• Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term Adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicenter trial. Aliment Pharmacol Ther. 2007;25:409–418.
   PubMed Web of Science ®Google Scholar
• De Groof EJ, Sahami S, Lucas C, et al. Treatment of perianal fistula in Crohn’s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016;18:667–675.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98–103.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45:933–940.
   PubMed Web of Science ®Google Scholar
• Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis. 2017;11:549–555.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Dignass A, Danese S, et al. European evidence‐based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–149.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150:1568–1578.
   PubMed Web of Science ®Google Scholar
• De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and Adalimumab in preventing Crohn’s disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther. 2015;42:867–879.
   PubMed Web of Science ®Google Scholar
• Cañete F, Mañosa M, Casanova MJ, et al. ENEIDA registry by GETECCU. Adalimumab or infliximab for the prevention of early post-operative recurrence of Crohn disease: results from the ENEIDA registry. Inflamm Bowel Dis. 2019;25:1862–1870.
   PubMed Web of Science ®Google Scholar
• Cañete F, Mañosa M, Prez-Martinez I, et al. Anti-tumor necrosis factor agents to treat endoscopic post-operative recurrence of Crohn’s disease: a nationwide study with propensity-matched score analysis. Clin Transl Gastroenterol. 2020;11:e00218.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opin Drug Saf. 2016;15:493–501.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Colombel J-F, et al. Five-year safety data from ENCORE, a european observational safety registry for adults with Crohn’s disease treated with infliximab [Remicade®] or conventional therapy. J Crohns Colitis. 2017;11:680–689.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Panaccione R, et al. Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn’s disease with up to 6 years of follow-up in the pyramid registry. Am J Gastroenterol. 2018;113:872–882.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti–tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–881.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel J-F, et al. Increased risk of malignancy with Adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146:941–949.e2.
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–1686.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.
   PubMed Web of Science ®Google Scholar
• Fischer A, Zundler S, Atreya R, et al. Differential effects of alpha4beta7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016;65:1642–1664.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–627.e3.
   PubMed Web of Science ®Google Scholar
• Zingone F, Barberio B, Compostella F, et al. Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario. Therap Adv Gastroenterol. 2020;13:1756284820936536.
   Web of Science ®Google Scholar
• Eriksson C, Rundquist S, Lykiardopoulos V, et al.; SWIBREG SVEAH Study Group. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicenter SVEAH study. Therap Adv Gastroenterol. 2021;14:17562848211023386.
   Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111:1147–1155.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab germany consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090–1102.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicenter cohort study. Aliment Pharmacol Ther. 2017;46:310–321.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Renna S, et al. Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naïve patients: a real-world multicenter study. United European Gastroenterol J. 2020;8:1045–1055.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Privitera G, Crispino F, et al., IG‐IBD LIVE Study Group. Effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022;56:95–109.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Ron Y, Avni-Biron I, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli real-world experience. Inflamm Bowel Dis. 2017;23:404–408.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the cross pennine study. Dig Liver Dis. 2018;50:1299–1304.
   PubMedGoogle Scholar
• Mocci G, Tursi A, Maconi G, et al. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study. Expert Opin Biol Ther. 2023;23:293–304.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Faggiani R, et al. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: a multicenter, observational study in primary inflammatory bowel disease centers. Eur J Intern Med. 2019;66:85–91.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Barnes EL, Stevens B, et al. Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with Vedolizumab. Dig Dis Sci. 2017;62:1590–1596.
   PubMed Web of Science ®Google Scholar
• Bressler B, Greenup A-J, Bassel M, et al. Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: interim results. J Crohns Colitis. 2018;12(suppl 1):S382.
   Google Scholar
• Helwig U, Mross M, Schubert S, et al. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review. BMC Gastroenterol. 2020;20:211.
   PubMed Web of Science ®Google Scholar
• Reenaers C, Cremer A, Dewit O, et al. Effectiveness and persistence of vedolizumab in patients with inflammatory bowel disease: results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE). Acta Gastroenterol Belg. 2020;83:15–23.
   PubMed Web of Science ®Google Scholar
• Onali S, Pugliese D, Caprioli FA, et al.; IG-IBD. An objective comparison of vedolizumab and ustekinumab effectiveness in Crohn’s disease patients’ failure to TNF-alpha inhibitors. Am J Gastroenterol. 2022;117:1279–1287.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199–1212.
   PubMed Web of Science ®Google Scholar
• Attauabi M, Madsen GR, Bendtsen F, et al. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysis. Dig Liver Dis. 2022;54:1168–1178.
   PubMedGoogle Scholar
• Attauabi M, Höglund C, Fassov J, et al. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol. 2021;56:1040–1048.
   PubMed Web of Science ®Google Scholar
• Cohen NA, Plevris N, Kopylov U, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterol J. 2020;8:1076–1085.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomised trial of patients with ulcerative colitis. Gastroenterology. 2020;158:562–572 e512.
   PubMed Web of Science ®Google Scholar
• Vermeire S, D’Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn’s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16:27–38.
   PubMed Web of Science ®Google Scholar
• Bergqvist V, Holmgren J, Klintman D, et al. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55:1389–1401.
   PubMed Web of Science ®Google Scholar
• Volkers A, Straatmijer T, Duijvestein M, et al. IBD center amsterdam and the dutch initiative on Crohn and Colitis. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;56:1044–1054.
   PubMed Web of Science ®Google Scholar
• Lim SH, Gros B, Sharma E, et al. Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: a multicenter study from the United Kingdom. Inflamm Bowel Dis. 2023 Aug 21;izad166. Epub ahead of print. PMID: 37603730. doi: 10.1093/ibd/izad166
   PubMed Web of Science ®Google Scholar
• Wiken TH, Høivik ML, Buer L, et al. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring. Scand J Gastroenterol. 2023;58:863–873.
   PubMedGoogle Scholar
• Ventress E, Young D, Rahmany S, et al. Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease [TRAVELESS]. J Crohns Colitis. 2022;16:911–921.
   PubMed Web of Science ®Google Scholar
• Hu Q, Tang XZ, Liu F, et al. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2023;16:17562848231166227.
   Web of Science ®Google Scholar
• Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of VDZ in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42:188–202.
   PubMed Web of Science ®Google Scholar
• Ayoub F, Odenwald M, Micic D, et al. Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis. Intest Res. 2022;20:240–250.
   PubMed Web of Science ®Google Scholar
• Chapuis-Biron C, Bourrier A, Nachury M, et al.; GETAID BioLAP Study Group. Vedolizumab for perianal Crohn’s disease: a multicenter cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51:719–727.
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: enterprise study. Clin Gastroenterol Hepatol. 2022;20:1059–1067.e.
   PubMed Web of Science ®Google Scholar
• Lemmens B, de Buck van Overstraeten A, Arijs I, et al. Submucosal plexitis as a predictive factor for post-operative endoscopic recurrence in patients with Crohn’s disease undergoing a resection with ileocolonic anastomosis: results from a prospective single-center study. J Crohns Colitis. 2017;11:212–220.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Taxonera C, Lopez-Sanroman A, et al. Prevention of post-operative recurrence of Crohn’s disease with vedolizumab: first results of the prospective placebo-controlled randomised trial REPREVIO. J Crohns Colitis. 2023;17(S1):i19.
   Google Scholar
• Yamada A, Komaki Y, Patel N, et al. The use of vedolizumab in preventing post-operative recurrence of Crohn’s disease. Inflamm Bowel Dis. 2018;24:502–509.
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Li T, Bachour SP, et al. Early initiation of anti-tumor necrosis factor therapy reduces post-operative recurrence of Crohn’s Disease following ileocecal resection. Inflamm Bowel Dis. 2023;29:888–897.
   PubMed Web of Science ®Google Scholar
• Mañosa M, Fernández-Clotet A, Nos P, et al. ENEIDA registry by GETECCU. Ustekinumab and vedolizumab for the prevention of post-operative recurrence of Crohn’s disease: results from the ENEIDA registry. Dig Liver Dis. 2023;55:46–52. • Interesting real-life study comparing ustekinumab and vedolizumab in preventing post-operative recurrence of the disease.
   PubMedGoogle Scholar
• Yanai H, Kagramanova A, Knyazev O, et al. Endoscopic post-operative recurrence in Crohn’s disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or Ustekinumab: a real-world multicenter European study. J Crohns Colitis. 2022;16:1882–1892.
   PubMed Web of Science ®Google Scholar
• Le Cosquer G, Altwegg R, Rivière P, et al. Prevention of post-operative recurrence of Crohn’s disease among patients with prior anti-TNFα failure: a retrospective multicenter study. Dig Liver Dis. 2023;55:727–734.
   PubMedGoogle Scholar
• Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicenter study. Aliment Pharmacol Ther. 2019;49:873–879.
   PubMed Web of Science ®Google Scholar
• Meserve J, Aniwan S, Koliani-Pace JL, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1533–1540.e2.
   PubMed Web of Science ®Google Scholar
• Dupré A, Collins M, Nocturne G, et al. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Rheumatology (Oxford). 2020;59:3275–3283.
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719–729.
   PubMed Web of Science ®Google Scholar
• Simons N, Degboé Y, Barnetche T, et al. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. Clin Exp Rheumatol. 2020;38:508–515.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of Ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2020;14:23–32.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20:578–590.e4.
   PubMed Web of Science ®Google Scholar
• Monin L, Dubois S. Reenaers C, et al.Ustekinumab in bio-naïve and bio-failure Crohn’s disease patients: results from a « real-life » monocentric cohort. Dig Liver Dis. 2021;53:72–78.
   PubMedGoogle Scholar
• Valdés Delgado T, Olmedo Martín R, Iborra M, et al. Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicenter observational retrospective study. Therap Adv Gastroenterol. 2023;16:17562848231153560.
   Web of Science ®Google Scholar
• Yao J, Zhang H, Su T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing crohn’s disease: a retrospective real-world analysis. J Clin Med. 2023;12:939.
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn Colitis. 2010;4:355–366.
   PubMed Web of Science ®Google Scholar
• Chowers A, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010;4:367–376.
   PubMed Web of Science ®Google Scholar
• Iborra M, Beltrán B, Fernández-Clotet A, et al. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2019;50:278–288.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Verstockt B, Gils A, et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13:1401–1409.
   PubMed Web of Science ®Google Scholar
• Biemans VBC, Van der Meulen-de Jong AE, Van der Woude CJ, et al. Ustekinumab for Crohn’s disease: results of the ICC registry, a nationwide prospective observational Cohort study. J Crohns Colitis. 2020;14:33–45.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Krisam J, Wehling C, et al. Ustekinumab: “Real-world” outcomes and potential predictors of non-response in treatment-refractory Crohn’s disease. World J Gastroenterol. 2019;25:4481–4492.
   PubMed Web of Science ®Google Scholar
• Eberl A, Hallinen T, Björkesten CG A, et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019;54:718–725.
   PubMed Web of Science ®Google Scholar
• Shitrit A B-G, Ben-Ya’acov A, Siterman M, et al. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: a multicenter Israeli study. United European Gastroenterol J. 2020;8:418–424.
   PubMed Web of Science ®Google Scholar
• Bennett A, Carlini LE, Duley C, et al. A single center experience with long-term Ustekinumab use and reinduction in patients with refractory Crohn disease. Crohns Colitis. 2020;360(2):1–5.
   Google Scholar
• Pugliese D, Daperno M, Fiorino G, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. Dig Liver Dis. 2019;51:972–977.
   PubMedGoogle Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicenter cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
   PubMed Web of Science ®Google Scholar
• Lorenzo González L, Valdés Delgado T, Vázquez Morón JM, et al. Grupo de Enfermedad Inflamatoria de Andalucía. Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response. Rev Esp Enferm Dig. 2022;114:272–279.
   PubMed Web of Science ®Google Scholar
• Bacaksız F, Arı D, Gökbulut V, et al. One-year real life data of our patients with moderate-severe Crohn’s disease who underwent ustekinumab therapy. Scott Med J. 2021;66:152–157.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Fries W, Viola A, et al. Effectiveness of ustekinumab on Crohn’s disease associated spondyloarthropathy: real-world data from the Sicilian network for inflammatory bowel diseases (SN-IBD). Expert Opin Biol Ther. 2020;20:1381–1384.
   PubMed Web of Science ®Google Scholar
• Viola A, Muscianisi M, Macaluso FS, et al. “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”Ustekinumab in Crohn’s disease: real-world outcomes from the Sicilian network for inflammatory bowel diseases. JGH Open. 2021;5:364–370.
   PubMed Web of Science ®Google Scholar
• Miranda A, Gravina AG, Cuomo A, et al. Efficacy of ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: a prospective observational real-life study. J Physiol Pharmacol. 2021 Epub 2021 Dec 31;72(4). doi:10.26402/jpp.2021.4.05
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Asano T, Nagano K, et al. Safety and effectiveness of ustekinumab in Crohn’s disease: interim results of post-marketing surveillance in Japan. J Gastroenterol Hepatol. 2021;36:3069–3076.
   PubMed Web of Science ®Google Scholar
• Yao JY, Zhang M, Wang W, et al. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study. BMC Gastroenterol. 2021;21:380.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Cuomo A, et al. Real-life efficacy and safety of ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study. Eur Rev Med Pharmacol Sci. 2021;25:2099–2108.
   PubMed Web of Science ®Google Scholar
• Scribano ML, Aratari A, Neri B, et al. Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicenter real-life study in Italy. Therap Adv Gastroenterol. 2022;15:17562848211072412.
   Web of Science ®Google Scholar
• Ylisaukko-Oja T, Puttonen M, Jokelainen J, et al. Dose-escalation of Adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterisation and implications in real-life clinical practice. Scand J Gastroenterol. 2022;57:415–423.
   PubMed Web of Science ®Google Scholar
• Parra RS, Chebli JMF, Queiroz NSF, et al. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study. BMC Gastroenterol. 2022;22:199.
   PubMed Web of Science ®Google Scholar
• Forss A, Clements M, Myrelid P, et al. PROSE SWIBREG study group; Olén O, Halfvarson J, Ludvigsson JF.Ustekinumab is associated with real-world long-term effectiveness and improved health-related quality of Life in Crohn’s disease. Dig Dis Sci. 2023;68:65–76.
   PubMed Web of Science ®Google Scholar
• Esaki M, Ihara Y, Tominaga N, et al. Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn’s disease: tertiary centers experience in Japan. Int J Colorectal Dis. 2023;38:57.
   PubMed Web of Science ®Google Scholar
• Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, et al. Effectiveness and safety of ustekinumab in elderly patients with Crohn’s disease: real world evidence from the ENEIDA registry. J Crohns Colitis. 2023;17:83–91.
   PubMed Web of Science ®Google Scholar
• Engel T, Yung DE, Ma C, et al. Effectiveness and safety of Ustekinumab for Crohn’s disease; systematic review and pooled analysis of real-world evidence. Dig Liver Dis. 2019;51:1232–1240.
   PubMedGoogle Scholar
• Macaluso FS, Maida M, Ventimiglia M, et al. Effectiveness and safety of ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther. 2020;20:193–203.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Venkata K, Zhang N, et al. Comparative effectiveness of ustekinumab versus adalimumab in induction of clinical response and remission in Crohn’s disease: experience of a real-world cohort at a tertiary care inflammatory bowel disease referral center. Gastroenterology Res. 2019;12:245–251.
   PubMed Web of Science ®Google Scholar
• Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51:948–957.
   PubMed Web of Science ®Google Scholar
• Singh S, Kim J, Luo J, et al. Comparative safety and effectiveness of biologic therapy for Crohn’s disease: a CA-IBD Cohort study. Clin Gastroenterol Hepatol. 2023;21:2359–2369.e5.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Adimadhyam S, Hou L, et al. Real-world evidence comparing vedolizumab and ustekinumab in anti-tumor necrosis factor-experienced patients with Crohn’s disease. Am J Gastroenterol. 2023;118:674–684.
   PubMed Web of Science ®Google Scholar
• Sedano R, Guizzetti L, McDonald C, et al. Clinical, endoscopic, and radiological effectiveness of ustekinumab in bio-naïve versus bio-experienced patients with Crohn’s disease: real-world experience from a large Canadian center. Inflamm Bowel Dis. 2023;29:866–874.
   PubMed Web of Science ®Google Scholar
• Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naïve patients with Crohn’s disease initiated on ustekinumab or Adalimumab. Curr Med Res Opin. 2023;39:533–543.
   PubMed Web of Science ®Google Scholar
• Johnson AM, Barsky M, Ahmed W, et al. The real-world effectiveness and safety of ustekinumab in the treatment of Crohn’s disease: results from the success consortium. Am J Gastroenterol. 2023;118:317–328.
   PubMed Web of Science ®Google Scholar
• Rivière P, Kanters C, Pellet G, et al. Comparative effectiveness of ustekinumab and anti-TNF agent as first-line biological therapy in luminal crohn’s disease: a retrospective study from 2 referral centers. Inflamm Bowel Dis. 2023;29:923–931.
   PubMed Web of Science ®Google Scholar
• Moens A, Alsoud D, Verstockt B, et al. Vermeire S.Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center. Eur J Gastroenterol Hepatol. 2022;34:1015–1020.
   PubMed Web of Science ®Google Scholar
• Shehab M, Alrashed F, Heron V, et al. Comparative efficacy of biologic therapies for inducing response and remission in fistulizing crohn’s disease: systematic review and network meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2023;29:367–375.
   PubMed Web of Science ®Google Scholar
• Chapuis-Biron C, Kirchgesner J, Pariente B, et al.; GETAID BioLAP Study Group. Ustekinumab for Perianal Crohn’s disease: the biolap multicenter study from the GETAID. Am J Gastroenterol. 2020;115:1812–1820.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Picchio M, et al. Maconi G.Letter: ustekinumab for the treatment of post-surgical and refractory Crohn’s disease. Aliment Pharmacol Ther. 2021;53:859–860.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Grova M, Mocciaro F, et al. Sicilian Network for Inflammatory Bowel Disease (SN-IBD).Ustekinumab is a promising option for the treatment of post-operative recurrence of Crohn’s disease. J Gastroenterol Hepatol. 2023;38:1503–1509.
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Maconi G. Effect of ustekinumab on extraintestinal diseases in refractory Crohn’s disease. J Crohns Colitis. 2021;15:1399–1400.
   PubMed Web of Science ®Google Scholar
• Godoy Brewer GM, Salem G, Afzal MA, et al. Ustekinumab is effective for perianal fistulizing Crohn’s disease: a real-world experience and systematic review with meta-analysis. BMJ Open Gastroenterol. 2021;8:e000702.
   PubMed Web of Science ®Google Scholar
• Mocci G, Bodini G, Allegretta L, et al. Adalimumab biosimilar GP2017 versus adalimumab originator in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study. Biomed. 2022;10:179.
   Google Scholar
• Mocci G, Cingolani A, Orrù G, et al. Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of Inflammatory Bowel Diseases patients when used as first biological treatment or as replace of the ADA originator for a non-medical reason. Front Gastroenterol. 2023;2:1218228.
   Google Scholar
• Holko P, Kawalec P, Pilc A. Cost-effectiveness analysis of crohn’s disease treatment with vedolizumab and ustekinumab after failure of tumor necrosis factor-α antagonist. Pharmacoeconomics. 2018;36:853–865.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2022;162:495–508.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. GALAXI-1 investigators.guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 galaxi-1 study. Gastroenterology. 2022;162:1650–1664.e8.
   PubMed Web of Science ®Google Scholar
• White JR, Phillips F, Monaghan T, et al. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:1610–1622.
   PubMed Web of Science ®Google Scholar